Compassionate use programmes are saving lives.
Patients seeking information

There is an abundance of health information, and in particular news about new products. The main source of information is the industry itself, in the “Investors” section of their website. This is often the main web pages to visit when you need accurate and timely information on the development status of any new medicine.

<table>
<thead>
<tr>
<th>Term</th>
<th>Number of hits on www</th>
<th>Number of articles in PubMed</th>
</tr>
</thead>
<tbody>
<tr>
<td>« promising new drug »</td>
<td>512 000</td>
<td>165</td>
</tr>
<tr>
<td>« promising new treatment »</td>
<td>402 000</td>
<td>325</td>
</tr>
<tr>
<td>« promising new cure »</td>
<td>23 500</td>
<td>557</td>
</tr>
</tbody>
</table>

Search done **15/05/2012**
A frequent situation

New drug being developed

New drug authorised

Some patients have no more treatment options, their condition deteriorates. Some die. They know some trials are in progress. When the drug is authorised, all patients can have access.

There is always one patient who will die the day before a drug is authorised and who knows the drug will be authorised next day.

For all, this is a nightmare.
Compassionate use is a response when a new drug is being developed and before it is authorised. But whenever a compassionate use programme starts, there will always be patients for whom it will be too late.
Example of

A SUCCESSFUL COMPASSIONATE USE PROGRAMME
The classical pathophysiology of HIV infection
A rapid CD4 recovery on HAART

Graph showing the median CD4 cell counts at baseline and during ART stratified by baseline CD4 cell count. Below the graph, the median (IQR) rates of CD4 cell increase (cells/μl/month) are given for phase 1 (0–16 weeks) and phase 2 (16–48 weeks) of immune recovery. Lawn et al. BMC Infectious Diseases 2006 6:59

-1.6 log = -97.5% HIV RNA
A success story
hospitalisation rates for 1000 AIDS patients, France 1995-1998

Results as salvage
2Q96 to 2Q97: - 56%

CUP: Compassionate Use Programme. Data from industry and BEH.
But to obtain this:

- A lottery had to be organised to distribute the first 250 treatments
- French Drug Agency requested Ethics Council opinion
- A group of 60 patients closed down an Abbott factory in Normandy 29/02/1996
- Simultaneously with FDA public hearing 29/02/1996
- As some 10,000 patients were expecting the new regimen
Hospitalisations first, then mortality declined

WHO: AIDS deaths
France, 1990 to 2009
EU legislation on compassionate use

A TRIBUTE TO HIV/AIDS ADVOCATES
History

• US: Aids activists urged FDA to accelerate regulatory process
  – March on Wall Street, on 24 March 24 1987
  – FDA adopted the compassionate use scheme

• France 1988
  – French activists negotiated early access with health authorities
  – 1991: ATU in Code de la Santé Publique

• Denmark: 1995
• Germany: 2005
• Italy: 2006
• Spain: 2009
Actions in Europe

• December 1999
  – European Aids Treatment Group (EATG) presented its analysis of time delays in access to new products between US and EU, and within EU

• January 2000
  – EATG press release “Aids activists fight for European wide early access to drugs”

• March 2000
  – Daniel Vittecoq sent his draft proposal to EATG on an new conditional approval procedure

• 2001 EATG responded to EC audit on the regulatory framework
  – and asked EC both for a compassionate use legislation and for conditional approval
EATG met CPMP on several occasions since April 1996

REPORT ON MEETING WITH THE EUROPEAN AIDS TREATMENT GROUP HELD ON 14 DECEMBER 1999

The CPMP met representatives of the European AIDS Treatment Group (EATG) on 14 December 1999 to exchange views and discuss information in relation to HIV/AIDS treatments. This meeting was the 3rd meeting of the CPMP and EATG held since 1995. Prof. Jean-Michel Alexandre chaired the meeting.

- EATG expressed their concern with respect to early access to promising medicinal products for HIV infected patients who have exhausted all available therapeutic options. EATG presented a comparison, which revealed a gap in access to new promising compounds through compassionate use programmes. Between the USA and the Member States of the European Union, the gap in access was up to 15 months. Within the European Union, additional differences exist between more sophisticated compassionate use systems in place in some Member States and less developed in others. Such differences in access may be due to strategies of the companies, lack of manufacturing production capacity and different national legislation or regulatory bodies being responsible within the Member States. It has been proposed to EATG that, during the Audit phase of the 2001 revision of the European system, they provide the Commission and the EMEA with a detailed report on the situation within the European Union explaining the practical difficulties and make proposals for improvement.
Data presented to CPMP

For HIV people in desperate need for new options: a persisting gap between US and EU

<table>
<thead>
<tr>
<th>Year</th>
<th>Drug</th>
<th>Delay Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>saquinavir (Invirase)</td>
<td>90 to 120 days delay between US and EU EAP</td>
</tr>
<tr>
<td></td>
<td>Nelfinavir (Viracept)</td>
<td>210 days between US and France, 420 days rest of EU</td>
</tr>
<tr>
<td></td>
<td>Abacavir (Ziagen)</td>
<td>150 to 900 days</td>
</tr>
<tr>
<td></td>
<td>Amprenavir (Agenerase)</td>
<td>60 to 390 days</td>
</tr>
<tr>
<td></td>
<td>Adefovir (Preveon)</td>
<td>450 days (only 1 EU state)</td>
</tr>
<tr>
<td></td>
<td>Norvir new capsule</td>
<td>30 days to &gt; 180</td>
</tr>
<tr>
<td>2000</td>
<td>Lopinavir ABT378/r</td>
<td>30 days to &gt; 150</td>
</tr>
<tr>
<td></td>
<td>2000 : tenofovir PMPA</td>
<td>&gt; 180 days</td>
</tr>
</tbody>
</table>
ATU provides access earlier than in any other EU MS, e.g. nelfinavir
Patients’ organisations could monitor the programme efficiency.
Patients’ organisations could monitor the programme efficiency

Sites with major differences in compassionate use prescriptions (% of patients compared to all patients treated with ritonavir or indinavir at national level)

<table>
<thead>
<tr>
<th>Site</th>
<th>Ritonavir</th>
<th>Indinavir</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burgundy</td>
<td>3.0%</td>
<td>0.2%</td>
</tr>
<tr>
<td>Nice</td>
<td>10.0%</td>
<td>2.0%</td>
</tr>
<tr>
<td>Bichat hosp</td>
<td>10.0%</td>
<td>2.3%</td>
</tr>
<tr>
<td>Necker hosp</td>
<td>5.8%</td>
<td>0.9%</td>
</tr>
<tr>
<td>Paris Est</td>
<td>4.0%</td>
<td>19.8%</td>
</tr>
<tr>
<td>Toulouse</td>
<td>5.1%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Rennes</td>
<td>3.0%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Rouen</td>
<td>1.0%</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
Running a Compassionate Use Programme (CUP) consists in making a medicinal product available for compassionate reasons to a group of patients:

- with a chronically or seriously debilitating disease
- or whose disease is considered to be life-threatening
- and who cannot be treated satisfactorily by an authorised medicinal product
All patients with the same disease in countries with CT

Patients eligible for clinical trials (CT)

(A) Clinical trials: experimental drug
(B) Clinical trials: placebo or control

When a marketing authorisation is granted

(C) Roll-over study

(D) Parallel access / track

When there is no marketing authorisation

(G) Patients treated via marketing authorisation

(H) Financial Assistance Programme

(E) Open label study, named patient basis, cohort...

(F) Open label study, named patient basis, cohort...

Compassionate Use Programme = (C) + (E) + (F)

Expanded Access Programme = CUP + (D) + (I) + (J) + (K) + ...

Patients representing an unmet medical need or with no suitable alternative available, and/or not eligible for CT

All patients with the same disease in countries with no CT

Patients representing an unmet medical need or with no suitable alternative available

CT recruitment terminates

Patients eligible for clinical trials (CT)
Compassionate use is not

- A clinical trial nor an experiment
  - intention is to treat
- A substitute to product development
  - It parallels clinical trials
- A financial help programme nor a humanitarian programme
- A way to place a product on the market prior to the marketing authorisation
- A “gift” to clinicians who achieve their objectives in recruiting for clinical trials
Eurordis Study

RECENT ORPHAN DRUG COMPANIES EXPERIENCE WITH CUP, IN EUROPE
Theme 6, Friday, 25 May 2012 11:00-12:30
Session 4: Compassionate Use Programmes
Co-Chairs: Etelka Czondi, and Arielle North

• Presentation 1: Presentation of main outcomes from EURORDIS ERTC workshop on 21/11/11
  – Speaker: Arielle North, Ancre consultant

• Presentation 2: Survey results: Overview of Recent Compassionate Use Programmes for OMPs and Issues Raised
  – Speaker: François Houÿez, EURORDIS, France

• Panel Discussion
## Responses

<table>
<thead>
<tr>
<th>Company</th>
<th>Product</th>
<th>Indication</th>
<th>CUP in Europe?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eusa Pharma</td>
<td>Inolimomab</td>
<td>Graft versus host disease</td>
<td>yes</td>
</tr>
<tr>
<td>Genzyme</td>
<td>Mozobil®</td>
<td>Treatment to mobilise progenitor cells prior to stem cell transplantation</td>
<td>yes</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>Vandetanib</td>
<td>Medullary thyroid carcinoma</td>
<td>yes</td>
</tr>
<tr>
<td>Merck Serono</td>
<td>Kuvan®</td>
<td>Hyperphenylalaninaemia (HPA) in adult and paediatric patients of 4 years + with (PKU)</td>
<td>yes</td>
</tr>
<tr>
<td>Orphan Europe</td>
<td>Carglumic acid</td>
<td>NAGS deficiency, isovaleric acidaemia, methylmalonic acidaemia</td>
<td>yes</td>
</tr>
<tr>
<td>Pharma Mar</td>
<td>Yondelis®</td>
<td>Soft Tissue Sarcoma</td>
<td>yes</td>
</tr>
<tr>
<td>Shire Pharmaceuticals</td>
<td>Velaglucerase alpha (Vpriv)</td>
<td>Gaucher type 1</td>
<td>Yes</td>
</tr>
<tr>
<td>Johnson&amp;Johnson</td>
<td>Decitabine</td>
<td>MDS</td>
<td>Yes</td>
</tr>
<tr>
<td>UCB</td>
<td>Xyrem®</td>
<td>Treatment of narcolepsy</td>
<td>No</td>
</tr>
<tr>
<td>Swedish Orphan BioVitrum</td>
<td>Kiobrina</td>
<td>Prevention of growth restriction in preterm infants</td>
<td>No</td>
</tr>
<tr>
<td>Chiesi Pharmaceutici</td>
<td>Ex vivo exp. auto. human corneal epithelium containing stem cells</td>
<td>Corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns</td>
<td>No</td>
</tr>
<tr>
<td>Novimmune</td>
<td>NI-0801</td>
<td>Haemophagocytic lymphohistiocytosis</td>
<td>No</td>
</tr>
<tr>
<td>Talecris Biother. Gmbh</td>
<td>Alpha-1-proteinase inhibitor</td>
<td>Congenital alpha-1 antitrypsin deficiency</td>
<td>No</td>
</tr>
<tr>
<td>Rare Partners sarl</td>
<td></td>
<td></td>
<td>No</td>
</tr>
<tr>
<td>Baxter</td>
<td></td>
<td></td>
<td>No</td>
</tr>
<tr>
<td>Dompé</td>
<td></td>
<td></td>
<td>No</td>
</tr>
<tr>
<td>FoldRx</td>
<td></td>
<td></td>
<td>No</td>
</tr>
</tbody>
</table>
Completed programmes (1)

Mozobil®

- Mozobil®

Designation ends
- M38
- M43
- M58
- M74

Pivotal recruit. ends
- CUP starts
- MA
- CUP ends
Completed programmes (2)

**Xyrem®**

- Designation
  - M17
  - M22
- CUP starts
- Pivot. recruit ends
  - M33
  - M36
- MA
- CUP ends

Months

0  5  10  15  20  25  30  35  40

Capacity building
A campaign to access

CIDOFOVIR, COMPASSIONATE USE FOR CYTOME戈LOVIRUS INFECTION
Cytomegalovirus infection
- In particular retinitis, transplant or HIV related
- Treatment before 1993: daily ganciclovir IV, foscarnet IV. Rapid resistance, blindness.
- Before dying of AIDS, patients became blind

Berlin 1993, World AIDS Conference
- results of a dose ranging trial I/II HPMPC to treat CMV viruria in HIV infection, by Polis & Jaffe
Preliminary efficacy results in 1995 CROI, Washington D.C.

CMV retinitis progression and cidofovir treatment immediate versus differed (n=28)

- **Immediate**:
  - No more lesions: 43%
  - Fewer lesions: 11%
  - Stable: 17%
  - Worsening: 10%

- **Differed**:
  - No more lesions: 50%
  - Fewer lesions: 30%
  - Stable: 36%
  - Worsening: 43%
11 April 1995: presentation of HPMPC at a public meeting

Philippe C. was affected by Cytomegalovirus, losing sight rapidly

Philippe asked me for information on this new treatment and how to access it immediately

Promised he would kill himself rather than becoming blind before dying of the Cytomegalovirus infection
1/ Search for someone who knew about it

- **Day 0, Paris, 11 April 95**
- Paris, April 95: French specialists had no idea where HPMPC development stood: “Development stopped”.
- Paris, April 95: contact with Andy Velez† in Act Up New York. Gilead Sciences identified.
- **Day 83, 3 July 95**: 1st contact with CEO John Martin.
- **Day 86, Foster City, 6 July**: encouraging response from Howard Jaffe, vice-pdt @ Gilead
2/ Contacts with national authorities

- Contact with ANRS, ADM, clinicians: there is a need, a demand. How do we organise this? Clinical controlled trial? Compassionate use programme? Open label trial?

- Looking for an industrial partner to help Gilead to deal with Europe. Contact with the ministry of health.

- Foster City, Sept 95: Pr J. Dormont (ANRS) met with Gilead. US Compassionate use programme started.

- Oct 95, FDA: New Drug Application file

- ADM asked Gilead to send copy of the file
3/ Early obstacles

- **Day 183, 11/10/1995**: French POs met with the ADM. Gilead did not send the data the agency was asking for.
- **Day 184, 12/10/1995**: Elisabeth Hubert, state secretary for health “invited” to finance the ATU programme
- **Day 211, 8/11**: due date for the secretary of health response
- But on 7 November: the French government resigned. 5 priorities passed to her successor, including cidofovir.
- **Day 227, 24/11**: Hervé Gaymard’s cabinet still not constituted.
- **Day 232, 29/11**: patients met with Hervé Gaymard who agreed to finance the compassionate use programme.
4/ More pressure from patients

Day 234-240, 1-7 Dec 1995: “ATU nominative” obtained. TRT5 informed French clinicians on the new possibility to prescribe cidofovir on a named patient basis. The ADM to answer each request between Christmas and New Year.

But still, product needed to be shipped to France

Day 240, 7 Dec 1995: Jean-François Lacronique, in charge of medical affairs at the French Embassy in Washington DC flow to Foster City to reinsure the company and to insist for data to be transmitted to ADM.

Day 248, 15 Dec 1995: Pr Christine Katlama contacted the minister to confirm clinicians’ interest.

Day 255, 22 Dec 1995: all data are at the ADM and EMEA.
5/ Endless financial issues

- **Day 294**, 30/01/96, Retrovirus conference, Washington DC: cidofovir confirmed as a major improvement
- **Day 296**, 1/02/96: ADM sent a request for export authorisation to Michele Li Moli, FDA.
- **Day 303**, 8/02/96: patients’ ultimatum over Gilead as progresses were too slow. Endless financial negotiations with Isotec (importer)
- **Day 313**, 18/02/96: patients urged the FDA and the French embassy in DC to accelerate the process.
6/ Finally

- **Day 325, 1 March 96:** Gilead staff visited the French CRO contracted for the ATU.
- Slow process since safety data must be cautiously monitored (renal toxicity and probenecid).
- **March 96:** TRT5 asked the Pharmacie Centrale des Hôpitaux to produce probenecid again (withdrawn)
- **Day 336, 12 March 96:** 1st French patient treated.
Epilogue

- This was 336 days after Philippe’s request.
- Best possible case scenario: company willing to help
- Philippe lost vision on 20 February 1996 and committed suicide the same day, as he promised he would do.
- This was 315 days after his request and 11 days before 1st patient treated.
- He used 2 bullets, his agony must have lasted for 6 hours according to forensic doctor.
- We had received 314 phone calls.
End of the story for the company: for being too focused on profits, no profits at all.
IN PRACTICE
Messages to industry

- Be prepared to work with POs as early as possible
  - e.g. Tibotec SOP on development programme, CT and DSMBs, pricing policy, and early access
  - Patients are member of COMP and create CABs – soon to come CHMP agendas
    - Early informed on what’s going on and dialogue with regulatory authorities (39 org. @ EMA)
Messages to industry

- Explain your production capacity planning
  - Stocks for CTs, stockpiling for filing, EAPs
- Consult when critical situations
  - E.g. 3TC expanded access 11/1994 +300% demand and 02/1005 +500% → pacing programme
  - Agree contingency plan with POs
Some Dos

- Define inclusion criteria for the compassionate use with patients and doctors
- Explain the plans country by country
- Accept no information on compassionate use programmes can be considered as confidential
- Collect information from the compassionate use programme, in particular toxicity data and special populations
And also

- Verify the terms of the programmes
  - E.g. “patients who are considered potentially unreliable” as exclusion criteria

- To identify compassionate use programmes, look for:
  - “expanded” or “compassionate” on https://www.clinicaltrialsregister.eu
  - Verify it is “open label”
  - You can also visit:

- E.g. compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) (open)

- E.g. compassionate use for thalidomide (closed)
Some “Don’t does”

1. Not enough supply to satisfy the demand
   - A lottery the less unethical method
   - But nobody will take the responsibility
   - Successful cases of “waiting list with shipment where drug most needed approach”
     - E.g. 3TC pacing programme 1994-1995

2. Programme ends
   - Continue providing drug to patients until price & reimbursement decision
   - Continue enrolling patients, or not: but be clear about it from the beginning
Some other “Don’t does”

3. Recruit in EAP as a gift to good regulatory trials recruiting sites
   - “for each patient in phase III, you’ll get one patient in a compassionate use programme”

4. Don’t mix compassionate use programmes with humanitarian or financial support programmes

5. Critical situations
   - POs can be consulted, but do not replace the responsible person
BACK UP SLIDES
## Hétérogénéité géographique

<table>
<thead>
<tr>
<th>Location</th>
<th>Bichat (10%)</th>
<th>Paris Est (4%)</th>
<th>Clermont Ferrand (3%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paris Centre</td>
<td>3%</td>
<td>Saint Louis (6%)</td>
<td>Tourcoing (1%)</td>
</tr>
<tr>
<td>Laennec</td>
<td>3%</td>
<td>Paris Sud (3%)</td>
<td>Martinique (1%)</td>
</tr>
<tr>
<td>Pitié</td>
<td>11%</td>
<td>CISIH 92 (7%)</td>
<td>Réunion (1%)</td>
</tr>
<tr>
<td>CISIH 93</td>
<td>3%</td>
<td>Bordeaux (6%)</td>
<td>Tours (1%)</td>
</tr>
<tr>
<td>Lyon</td>
<td>1%</td>
<td>Caen (2%)</td>
<td>Guadeloupe (1%)</td>
</tr>
<tr>
<td>Grenoble</td>
<td>1%</td>
<td>Marseille (10%)</td>
<td>Rennes (3%)</td>
</tr>
<tr>
<td>Nancy</td>
<td>3%</td>
<td>Bourgogne (3%)</td>
<td>Toulouse (0%)</td>
</tr>
<tr>
<td>Nantes</td>
<td>3%</td>
<td>Strasbourg (2%)</td>
<td>Montpellier (1%)</td>
</tr>
<tr>
<td>Nice</td>
<td>10%</td>
<td>Rouen (1%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>--------</td>
<td>----------</td>
<td>------</td>
</tr>
<tr>
<td><strong>Broussais</strong></td>
<td>3 %</td>
<td><strong>Cochin</strong></td>
<td>4 %</td>
</tr>
<tr>
<td><strong>H. Mondor</strong></td>
<td>2 %</td>
<td><strong>Pitié</strong></td>
<td>23 %</td>
</tr>
<tr>
<td><strong>Louis Mourier</strong></td>
<td>4 %</td>
<td><strong>Poincaré</strong></td>
<td>3 %</td>
</tr>
<tr>
<td><strong>Rotschild</strong></td>
<td>2 %</td>
<td><strong>Saint Louis</strong></td>
<td>13 %</td>
</tr>
<tr>
<td><strong>Saint Antoine</strong></td>
<td>6 %</td>
<td><strong>Necker</strong></td>
<td>2 %</td>
</tr>
<tr>
<td><strong>A. Paré</strong></td>
<td>2 %</td>
<td><strong>Avicenne</strong></td>
<td>3 %</td>
</tr>
<tr>
<td><strong>Bicêtre</strong></td>
<td>3 %</td>
<td><strong>Bichat</strong></td>
<td>22 %</td>
</tr>
<tr>
<td><strong>Beclère</strong></td>
<td>4 malades</td>
<td><strong>Garches</strong></td>
<td>31 malades</td>
</tr>
<tr>
<td>CisiH</td>
<td>En cours</td>
<td>CisiH</td>
<td>En cours</td>
</tr>
<tr>
<td>------------</td>
<td>----------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>Bourgogne</td>
<td>3</td>
<td>Bichat</td>
<td>39</td>
</tr>
<tr>
<td>Bordeaux</td>
<td>60</td>
<td>Cochin</td>
<td>150</td>
</tr>
<tr>
<td>Caen</td>
<td>24</td>
<td>Necker</td>
<td>100</td>
</tr>
<tr>
<td>Grenoble</td>
<td>58</td>
<td>Paris Sud</td>
<td>82</td>
</tr>
<tr>
<td>Lyon</td>
<td>49</td>
<td>Salpêtrière</td>
<td>159</td>
</tr>
<tr>
<td>Marseille</td>
<td>137</td>
<td>Saint Louis</td>
<td>39</td>
</tr>
<tr>
<td>Nancy</td>
<td>25</td>
<td>Paris Est</td>
<td>341</td>
</tr>
<tr>
<td>Nantes</td>
<td>27</td>
<td>CisiH 92</td>
<td>76</td>
</tr>
<tr>
<td>Nice</td>
<td>35</td>
<td>CisiH 93</td>
<td>66</td>
</tr>
<tr>
<td>Guyane</td>
<td>1</td>
<td>La Réunion</td>
<td>7</td>
</tr>
</tbody>
</table>